Fish oil for gynaecomastia is a topic that attracts considerable interest online, yet the clinical evidence tells a very different story. Gynaecomastia — the benign enlargement of glandular breast tissue in males — affects an estimated 30–60% of men at some point in their lives and can cause significant physical discomfort and psychological distress. Whilst omega-3 fatty acids found in fish oil have recognised anti-inflammatory properties, many men wonder whether supplementation could correct the hormonal imbalance driving breast tissue growth. This article examines what the evidence actually shows, outlines recognised UK treatments, and explains when to seek medical advice.

What Is Gynaecomastia and What Causes It?

Gynaecomastia is benign glandular breast tissue enlargement in males caused by an oestrogen-to-androgen imbalance; causes include puberty, medications, systemic illness, and idiopathic factors in up to 25% of cases.

Gynaecomastia (sometimes spelled 'gynecomastia' in US sources) refers to the benign enlargement of glandular breast tissue in males, resulting in a firm or rubbery mass beneath the nipple area. It is distinct from pseudogynaecomastia, which involves fatty tissue accumulation without true glandular growth. Gynaecomastia is surprisingly common, affecting an estimated 30–60% of males at some point during their lifetime, with peaks occurring during neonatal development, puberty, and older adulthood.

The underlying cause is typically an imbalance between oestrogen and androgen activity in breast tissue. Oestrogens stimulate glandular proliferation, whilst androgens — primarily testosterone — counteract this effect. When this balance shifts in favour of oestrogen, either through increased oestrogen production, reduced testosterone levels, or heightened tissue sensitivity, gynaecomastia can develop.

A wide range of factors can contribute to this hormonal imbalance, including:

• Physiological causes: puberty, ageing, and neonatal oestrogen exposure

• Medical conditions: hypogonadism, hyperthyroidism, liver cirrhosis, chronic kidney disease, and testicular tumours

• Medications: spironolactone, cimetidine, finasteride, dutasteride, bicalutamide, GnRH analogues, ketoconazole, digoxin, efavirenz, anabolic steroids, some antipsychotics, and certain antiretrovirals

• Recreational substances: alcohol and anabolic steroids; cannabis has been suggested as a possible association, though the evidence is not definitive

• Idiopathic causes: no identifiable cause found in up to 25% of cases

It is important to distinguish true gynaecomastia from breast cancer, which, although rare in males, can present similarly. Any unilateral, hard, irregular, or rapidly growing breast lump warrants prompt medical evaluation.

In line with NICE CKS guidance on gynaecomastia, a thorough clinical history, physical examination, and targeted investigations are recommended to identify any underlying cause before considering treatment options. Investigations typically include serum testosterone, luteinising hormone (LH), follicle-stimulating hormone (FSH), oestradiol, prolactin, human chorionic gonadotrophin (hCG), thyroid-stimulating hormone (TSH), liver function tests (LFTs), and renal profile. Testicular examination is an essential part of the clinical assessment; testicular ultrasound should be arranged where a testicular abnormality is suspected, and breast imaging considered where malignancy cannot be excluded clinically.

Fish Oil and Hormonal Balance: What the Evidence Shows

There is no robust clinical evidence that fish oil reduces gynaecomastia; theoretical effects on aromatase and SHBG remain unproven in human trials, and no UK clinical guidelines recommend it as a treatment.

Fish oil is a widely used dietary supplement derived primarily from oily fish such as mackerel, sardines, and salmon. It is rich in omega-3 polyunsaturated fatty acids (PUFAs), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These fatty acids have recognised anti-inflammatory properties. It is important to distinguish between over-the-counter (OTC) fish oil food supplements and licensed omega-3 medicines: the UK-licensed prescription product Omacor (omega-3-acid ethyl esters 90) has a specific licensed indication for hypertriglyceridaemia and, in combination with a statin, for secondary prevention following myocardial infarction, as detailed in its Summary of Product Characteristics (SmPC) on the Electronic Medicines Compendium (EMC). NICE TA805 provides guidance on icosapent ethyl (a purified EPA product) for cardiovascular risk reduction in selected high-risk patients on statin therapy. The cardiovascular evidence for general OTC omega-3 supplements is considerably more limited and should not be conflated with that for these prescription medicines.

Some individuals search for fish oil as a potential remedy for gynaecomastia, often based on the premise that omega-3 fatty acids may influence sex hormone levels. There is limited laboratory-based evidence suggesting that omega-3 PUFAs can modestly affect steroidogenesis and may influence sex hormone-binding globulin (SHBG) concentrations. Some sources also cite a theoretical effect on aromatase activity — the enzyme that converts androgens into oestrogens. Whilst these mechanisms are biologically plausible at a cellular level, they remain unproven in human clinical studies and should be regarded as speculative.

There is currently no robust clinical evidence from well-designed human trials demonstrating that fish oil supplementation reduces glandular breast tissue in males or meaningfully corrects the oestrogen-to-androgen imbalance responsible for gynaecomastia. Specifically:

• No clinical guidelines from NICE, the NHS, or the MHRA recommend fish oil as a treatment for gynaecomastia

• Anecdotal reports should not be substituted for evidence-based medical advice

• Supplementation does not address the underlying hormonal or pathological cause

In summary, whilst fish oil food supplements are widely used, there is no established clinical link between fish oil supplementation and the resolution of gynaecomastia. Individuals should not delay seeking medical assessment in favour of self-treating with supplements.

Recognised Treatments for Gynaecomastia in the UK

Gynaecomastia management in the UK ranges from watchful waiting in adolescents to off-label tamoxifen or raloxifene for early symptomatic cases, and subcutaneous mastectomy for persistent fibrotic disease.

Management of gynaecomastia in the UK is guided by the underlying cause, the duration of the condition, and the degree of physical or psychological impact on the individual. In many cases — particularly during puberty — gynaecomastia resolves spontaneously within six to twenty-four months without any specific intervention. Reassurance and watchful waiting are therefore appropriate first-line approaches in adolescents with no identifiable pathological cause, as outlined in NICE CKS guidance on gynaecomastia.

Where an underlying condition or causative medication is identified, addressing that root cause is the primary treatment strategy. For example, discontinuing a causative drug, treating hypogonadism with testosterone replacement therapy, or managing hyperthyroidism may lead to gradual regression of breast tissue.

For persistent or symptomatic gynaecomastia, the following options may be considered:

• Pharmacological treatment: Medications such as tamoxifen (a selective oestrogen receptor modulator) or raloxifene have been used off-label in the UK with some evidence of benefit, particularly in early or tender gynaecomastia. These are not formally licensed for this indication but may be prescribed by specialists. Medical therapy is generally most effective when gynaecomastia is of recent onset (typically within six to twelve months), before fibrotic changes become established. Aromatase inhibitors are not routinely recommended outside specialist care, given limited efficacy data and their adverse effect profile. Refer to the BNF for dosing and safety information on tamoxifen and raloxifene.

• Surgical treatment: Subcutaneous mastectomy or liposuction-assisted surgery is the most definitive treatment for established, fibrotic gynaecomastia that has not responded to other measures. Referral to a plastic or breast surgeon is appropriate in such cases.

• Psychological support: Given the significant impact gynaecomastia can have on self-esteem and mental wellbeing, psychological support or counselling may be beneficial alongside physical treatment.

Referral pathways should reflect the clinical findings: suspected hormonal or systemic causes warrant referral to endocrinology; persistent or fibrotic breast masses should be referred to a breast clinic or plastic surgery; and testicular pathology identified on examination should prompt urgent urology referral. Patients should be aware that cosmetic surgical procedures for gynaecomastia are generally not funded by the NHS unless strict clinical criteria are met.

Safety Considerations and When to See Your GP

Fish oil supplements are generally safe but should not replace medical assessment; see your GP promptly for any new, unilateral, hard, or rapidly growing breast lump, as this may warrant urgent cancer pathway referral.

Fish oil food supplements are generally considered safe for most adults when taken at commonly recommended intakes. It is important to note that fish oil supplements sold in the UK are regulated as foods under UK food law, overseen by the Food Standards Agency (FSA) and the Office for Product Safety and Standards (OPSS) — they are not regulated by the MHRA. The MHRA regulates licensed omega-3 medicines (such as Omacor and icosapent ethyl) and is responsible for medicines pharmacovigilance.

When considering fish oil supplements, it is more informative to look at the combined EPA and DHA content rather than the total oil volume, as products vary considerably in their omega-3 concentration. You should not exceed the dose stated on the product label unless advised to do so by a clinician. At commonly used supplemental intakes, fish oil is generally well tolerated, though the following effects have been reported:

• Gastrointestinal symptoms: nausea, loose stools, or a fishy aftertaste

• Increased bleeding tendency: individuals taking warfarin should have their INR monitored when starting or stopping high-dose omega-3 supplements, as these may affect anticoagulant control; caution is also advised for those taking direct oral anticoagulants (DOACs) or antiplatelet medicines — seek advice from your GP or pharmacist before starting supplements

If you think you are experiencing a side effect from a fish oil supplement or any omega-3 medicine, you can report it through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

Whilst fish oil is unlikely to cause harm when used appropriately, relying on it as a primary treatment for gynaecomastia carries its own risks — chiefly the risk of delaying a proper diagnosis. Gynaecomastia can occasionally be a sign of a serious underlying condition, including testicular cancer or a hormone-secreting tumour, which requires timely investigation.

You should contact your GP promptly if you notice:

• A new or growing lump in one or both breasts

• Breast pain, tenderness, or nipple discharge

• Rapid or unexplained breast enlargement

• Associated symptoms such as fatigue, weight changes, or reduced libido

• A lump, pain, or swelling in a testicle

• Breast changes alongside use of anabolic steroids or new medications

Your GP will take a thorough history, perform a clinical examination, and arrange appropriate blood tests or imaging if indicated. Early assessment is particularly important if the lump is unilateral, hard, or associated with skin changes. In line with NICE NG12 (Suspected Cancer: Recognition and Referral), these features may warrant urgent referral under the two-week wait cancer pathway. Similarly, any suspicious testicular finding should prompt urgent assessment.

In conclusion, whilst fish oil food supplements are widely used, there is no credible clinical evidence supporting their use as a treatment for gynaecomastia. Anyone concerned about breast tissue changes should seek professional medical advice rather than relying on unproven supplementation strategies.

Have questions about your medication? Our pharmacists are here to help →

Frequently Asked Questions